Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin
Yoshikiyo Ito, Toshihiro Miyamoto, Yong Chong, et al.
International Journal of Hematology (2012) Vol. 97, Iss. 1, pp. 135-138
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

From obesity to diabetes and cancer: epidemiological links and role of therapies
Custodia García‐Jiménez, María Teresa Gutiérrez‐Salmerón, Ana Chocarro‐Calvo, et al.
British Journal of Cancer (2016) Vol. 114, Iss. 7, pp. 716-722
Open Access | Times Cited: 150
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
Carlo G. Tocchetti, Christian Cadeddu Dessalvi, Daniela Di Lisi, et al.
Antioxidants and Redox Signaling (2017) Vol. 30, Iss. 18, pp. 2110-2153
Open Access | Times Cited: 114
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis, Paul Lee, Donald Zimmerman, et al.
Pediatric Blood & Cancer (2016) Vol. 63, Iss. 8, pp. 1332-1338
Closed Access | Times Cited: 65
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML
Peter Valent, Emir Hadzijusufovic, Gregor Hoermann, et al.
Leukemia Research (2017) Vol. 59, pp. 47-54
Open Access | Times Cited: 65
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events
Ali Manouchehri, Elishama Kanu, Michael J. Mauro, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2019) Vol. 40, Iss. 2, pp. 301-308
Open Access | Times Cited: 56
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, et al.
Oncotarget (2015) Vol. 6, Iss. 32, pp. 33944-33951
Open Access | Times Cited: 61
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
Takudzwa Mugiya, Mamosheledi Mothibe, Andile Khathi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Toceranib phosphate‐associated diabetes mellitus in a dog
Shu Min Chan, C. Prior, Christine Sesanto, et al.
Veterinary Record Case Reports (2025)
Closed Access
Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib
Nehal M. Elsherbiny, Mohamed El‐Sherbiny, Eman Said
Journal of Physiology and Biochemistry (2015) Vol. 71, Iss. 4, pp. 635-648
Closed Access | Times Cited: 26
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Hélène Haguet, Jonathan Douxfils, C Chatelain, et al.
TH Open (2018) Vol. 02, Iss. 01, pp. e68-e88
Open Access | Times Cited: 26
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
P. Buffier, Benjamin Bouillet, Sarra Smati, et al.
Annales d Endocrinologie (2018) Vol. 79, Iss. 5, pp. 574-582
Closed Access | Times Cited: 26
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
Adrian Minson, Katherine D. Cummins, Lucy C. Fox, et al.
Blood Advances (2019) Vol. 3, Iss. 7, pp. 1084-1091
Open Access | Times Cited: 23
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes
Rana Malek, Stephen N. Davis
Expert Opinion on Investigational Drugs (2016) Vol. 25, Iss. 3, pp. 287-296
Closed Access | Times Cited: 21
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database
Naoto Okada, Takahiro Niimura, Yoshito Zamami, et al.
Cancer Medicine (2018) Vol. 8, Iss. 1, pp. 174-181
Open Access | Times Cited: 21
RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice
Brittany M. Duggan, Joseph F. Cavallari, Kevin P. Foley, et al.
Endocrinology (2020) Vol. 161, Iss. 8
Open Access | Times Cited: 19
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy
Zdeněk Ráčil, Eva Koriťáková, Tomasz Sacha, et al.
American Journal of Hematology (2018) Vol. 93, Iss. 10
Open Access | Times Cited: 17
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
Zeng Wang, Liyu Jiang, Hao Yan, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 4, pp. 445-456
Closed Access | Times Cited: 14
Exploring the recent molecular targets for diabetes and associated complications
Amit Gupta, Tapan Behl, Aayush Sehgal, et al.
Molecular Biology Reports (2021) Vol. 48, Iss. 3, pp. 2863-2879
Closed Access | Times Cited: 12
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia
Mariko Yoshimura, Kensuke Kojima, Rika Tomimasu, et al.
International Journal of Hematology (2014) Vol. 100, Iss. 6, pp. 611-614
Closed Access | Times Cited: 13
Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia
Yuichiro Iwamoto, Tomohiko Kimura, Hideyuki Iwamoto, et al.
Internal Medicine (2024)
Open Access | Times Cited: 1
Tyrosine Kinase Targeting
Mohammad Althubiti
Saudi Journal of Medicine and Medical Sciences (2022) Vol. 10, Iss. 3, pp. 183-191
Open Access | Times Cited: 7
Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin
Brittany M. Duggan, Daniel M. Marko, Raveen Muzaffar, et al.
Journal of Endocrinology (2022)
Open Access | Times Cited: 7
Nilotinib enhances β-islets integrity and secretory functions in a rat model of STZ-induced diabetes mellitus
Mahmoud M. Samaha, Eman Said, Hatem A. Salem
European Journal of Pharmacology (2019) Vol. 860, pp. 172569-172569
Closed Access | Times Cited: 10
Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia
Lando Janssen, Maria T. E. Hopman, Greetje J. A. Swaans, et al.
AJP Endocrinology and Metabolism (2023) Vol. 324, Iss. 3, pp. E209-E216
Closed Access | Times Cited: 3
Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National PopulationBased Cohort Study
Cih‐En Huang, Kuan‐Der Lee, Jung-Jung Chang, et al.
The Oncologist (2023) Vol. 29, Iss. 1, pp. e81-e89
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top